Showing results (2741-2750 of 3,679) with videos related to

Sort By:
Pageof 368
Evidence Report/Technology Assessment|May 5, 2009
Management of chronic hepatitis BTimothy J Wilt, Tatyana Shamliyan, Aasma Shaukat, et al.
Epidemiology and Infection|May 15, 2001
Risk factors for meningococcal disease in university halls of residenceS J Nelson, A Charlett, H J Orr, et al.
The Journal of Rheumatology|January 17, 2019
MRI and Dose Selection in a Phase II Trial of Baricitinib with Conventional Synthetic Disease-modifying Antirheumatic Drugs in Rheumatoid ArthritisCharles Peterfy, Julie DiCarlo, Paul Emery, et al.
The Journal of Thoracic and Cardiovascular Surgery|November 1, 1986
Predictors of reoperation after myocardial revascularizationD M Cosgrove, F D Loop, B W Lytle, et al.
European Journal of Pain (London, England)|September 15, 2025
Differences Among Veterans With Chronic Overlapping Pain Conditions and Other Chronic Pain: Baseline Results From the LAMP Pain Management TrialJenna L Adamowicz, Alexis Grant, Collin Calvert, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|July 17, 2014
Patient-reported outcomes and health-related quality of life in prostate cancer treated with a single fraction of high dose rate brachytherapy combined with hypofractionated external beam radiotherapyA Choudhury, C Arthur, J Malik, et al.
Rheumatology and Therapy|January 20, 2023
Patient Disease Trajectories in Rheumatoid Arthritis Patients Treated with Baricitinib 4-mg in Four Phase 3 Clinical StudiesPeter C Taylor, Yun-Fei Chen, Janet Pope, et al.
Annals of Surgery|October 1, 1985
Determinants of 10-year survival after primary myocardial revascularizationD M Cosgrove, F D Loop, B W Lytle, et al.
Neurology|January 16, 2008
Volumetric MRI vs clinical predictors of Alzheimer disease in mild cognitive impairmentA S Fleisher, S Sun, C Taylor, et al.
Advances in Therapy|February 21, 2023
Baricitinib Safety for Events of Special Interest in Populations at Risk: Analysis from Randomised Trial Data Across Rheumatologic and Dermatologic IndicationsPeter C Taylor, Thomas Bieber, Rieke Alten, et al.
Pageof 368